RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00035024.xml
PDF herunterladen
Thromb Haemost 1998; 79(03): 684-685
DOI: 10.1055/s-0037-1614966
DOI: 10.1055/s-0037-1614966
Letters to the Editor
High Prevalence of Factor V R506Q Mutation in German Thrombophilic and Normal Population
Weitere Informationen
Publikationsverlauf
Received
18. September 1998
Accepted
13. Oktober 1998
Publikationsdatum:
07. Dezember 2017 (online)
-
References
- 1 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.. Proc Natl Acad Sci USA 1993; 90: 1004-8.
- 2 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C.. Nature 1994; 369: 64-7.
- 3 Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va.. Lancet 1994; 343: 1361-2.
- 4 Griffin JH, Evatt B, Widermann C, Fernandez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients.. Blood 1993; 82: 1989-93.
- 5 Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study.. Lancet 1993; 342: 1503-6.
- 6 Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis.. N Engl J Med 1994; 330: 517-22.
- 7 Nowak-Göttl U, Koch HG, Aschka I, Kohlhase B, Vielhaber H, Kurlemann G, Oleszuk-Raschke K, Kehl HG, Jürgens H, Schneppenheim R. Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism.. Brit J Haematol 1996; 92: 992-6.
- 8 De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia. Pathogenesis, clinical syndromes and management.. Blood 1996; 87: 3531-44.
- 9 Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men.. N Engl J Med 1995; 332: 912-7.
- 10 Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden.. Lancet 1995; 346: 1133-4.
- 11 Ehrenforth S, Radtke KP, Scharrer I. Acquired activated protein C resistance in patients with lupus anticoagulants.. Thromb Haemost 1995; 74 (Suppl. 02) 797-8.
- 12 Ashka I, Aumann V, Bergmann F, Budde U, Eberl W, Eckhof-Donovan S, Krey S, Nowak-Göttl U, Schobeß R, Sutor AH, Wendisch J, Schneppen heim R. Prevalence of factor V Leiden in children with thromboembolism.. Eur J Pediatr 1996; 155: 1009-14.
- 13 März W, Seydewitz H, Winkelmann B, Chen M, Nauck M. Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease.. Lancet 1995; 354: 526-7.
- 14 Schröder W, Koessling M, Wulff K, Wehnert M, Hermann FH. Large-scale screening for factor V Leiden mutation in a north-eastern German population.. Lancet 1996; 347: 58-9.
- 15 De Stefano V, Leone G. Resistance to activated protein C due to mutated Factor V as a novel cause of inherted thrombophilia.. Haematologica 1995; 80: 346-58.
- 16 Mannucci PM, Duca F, Peyvandi F, Tagliabue L, Merati G, Martineli I, Cattaneo M. Frequency of Factor V Arg506Gln in Italians.. Thromb Haemost 1996; 75: 694.
- 17 Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (Activated protein C resistance).. Blood 1995; 85: 1504-8.